Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, has closed a structured debt financing with Capital Royalty Partners LP, providing the company with up to $20 million of capital.
Read More
The National Cancer Institute has awarded Insight Genetics a $1.5 million Phase II continuation of its SBIR contract for developing a companion diagnostic to assess patient resistance to therapies for non-small cell lung cancer.
Read More
An electronic forms and reporting module from the College of American Pathologists and mTuitive helps pathologists report cancer findings.
Read More
A test developed by researchers at the University of Chicago has the potential to help physicians identify patients with the most lethal forms of triple-negative breast cancer, a disease that requires aggressive and innovative treatment.
Read MoreMolecular diagnostics company Biodesix announced that it has closed $8.4 million in Series E financing. The capital will help develop the company’s mass-spec technology platform and market the company’s first test, VeriStat, to guide NSCLC therapy.
Read More